Trial Profile
A Phase II study of TSU-68 in patient with hepatocellular carcinoma who are treated by transcatheter arterial chemoembolization (TACE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Orantinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 15 Aug 2013 New trial record
- 10 Jun 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 30 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.